STEP-1, a 2021 study in New England Journal of Medicine , tested weekly semaglutide 2.4 mg (the molecule in Wegovy) in adults with overweight or obesity
Although GI AEs are common across all GLP-1 RAs, differences in formulation, dosing, and dual agonism with tirzepatide can influence how well patients tolerate therapy
Lower A1C Fast Maximize blood sugar reduction Lose Weight Weight loss is a priority Protect Organs Heart & kidney protection Yes I have heart disease, heart failure, or chronic kidney disease No No known heart or kidney conditions Prefer Pills I'd rather take oral medications Open to Injections If it's more effective, I'm open to injectables Yes, Cost Matters I need affordable/generic options Less Concerned I have good insurance or can afford newer medications Your Personalized Recommendation Remember: This tool provides educational guidance only
Unlike direct HGH injections, it supports a more physiologic pattern of GH release
Whatever caused the lean mass loss, it wasn't unique to the drug